- Research works
- 90 ▲ 88% vs 2013–17
- Citations
- 2.1k 23.0 per fractional work
- Top-10% rate
- 19.6% record average 16.5%
- Open access
- 35% world 28%
Not ranked overall: GEICAM – Spanish Breast Cancer Group is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.4×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 4.4×
- Medicine 3.6×
- Earth and Planetary Sciences 1.0×
- Immunology and Microbiology 0.9×
- Nursing 0.8×
- Economics, Econometrics and Finance 0.7×
- Environmental Science 0.2×
- Neuroscience 0.2×
- Engineering 0.1×
- Energy 0.1×
- Social Sciences 0.1×
- Agricultural and Biological Sciences 0.0×
- Chemistry 0.0×
- Health Professions 0.0×
Who are the top researchers at GEICAM – Spanish Breast Cancer Group?
Ranked on the composite score, Eva Carrasco, Rosalía Caballero and Lourdes Calvo lead among researchers whose main affiliation is GEICAM – Spanish Breast Cancer Group.
- 1 Eva Carrasco Spain · #399,921 worldwide 115 citations · 30 works
- 2 Rosalía Caballero Spain · #584,493 worldwide 74 citations · 19 works
- 3 Lourdes Calvo Spain · #610,009 worldwide 52 citations · 21 works
Which keywords describe research at GEICAM – Spanish Breast Cancer Group?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Breast Cancer, Metastatic Breast Cancer, Chemotherapy, Clinical Practice Guidelines, Prognostic Markers, Radiotherapy, Survival Analysis and Molecular Subtypes.
- Targeted Therapy
- Body Mass Index
- Tumor Microenvironment
- Metastasis
- Metabolic Syndrome
- Taxanes
- EGFR
- Quality of Life
- Treatment Response
- Palbociclib
- CDK4/6 Inhibitors
- Molecular Subtypes
- Radiotherapy
- Clinical Practice Guidelines
- Metastatic Breast Cancer
- Breast Cancer
- Chemotherapy
- Prognostic Markers
- Gene Expression
- Survival Analysis
- Neoadjuvant Therapy
- Breast Tumours
- Cancer
- Chemotherapy-Induced Peripheral Neuropathy
- HER2
- Trastuzumab
- Obesity
- Survival
- Adiposity
- Pregnancy
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 30 words, with their numbers
- Breast Cancer8▲ 125×9 topics
- Metastatic Breast Cancer6▲ 373×2 topics
- Chemotherapy4▲ 25×14 topics
- Clinical Practice Guidelines4▲ 26×7 topics
- Prognostic Markers4▲ 134×3 topics
- Radiotherapy4▲ 36×6 topics
- Gene Expression4▲ 22×5 topics
- Molecular Subtypes4▲ 161×3 topics
- Survival Analysis4▲ 50×4 topics
- CDK4/6 Inhibitors3▲ 529×1 topic
- Neoadjuvant Therapy3▲ 56×2 topics
- Palbociclib3▲ 529×1 topic
- Breast Tumours3▲ 270×1 topic
- Treatment Response3▲ 270×1 topic
- Cancer3▲ 8.1×16 topics
- Quality of Life3▲ 7.5×5 topics
- Chemotherapy-Induced Peripheral Neuropathy2▲ 249×1 topic
- EGFR2▲ 266×1 topic
- HER22▲ 266×1 topic
- Taxanes2▲ 249×1 topic
- Trastuzumab2▲ 171×2 topics
- Metabolic Syndrome2▲ 6.9×8 topics
- Obesity1▲ 7.4×7 topics
- Metastasis1▲ 15×7 topics
- Survival1▲ 37×3 topics
- Tumor Microenvironment1▲ 11×5 topics
- Adiposity1▲ 95×1 topic
- Body Mass Index1▲ 95×1 topic
- Pregnancy1▲ 23×2 topics
- Targeted Therapy1▲ 21×4 topics
Which research topics does GEICAM – Spanish Breast Cancer Group publish most on?
By volume in 2022–2025: Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research and Cancer Treatment and Pharmacology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 3 works
- 2 Breast Cancer Treatment Studies Cancer Research 3 works
- 3 HER2/EGFR in Cancer Research Oncology 2 works
- 4 Cancer Treatment and Pharmacology Oncology 2 works
- 5 Cancer Risks and Factors Oncology 1 works
- 6 Cancer Genomics and Diagnostics Cancer Research 1 works
- 7 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 8 Estrogen and related hormone effects Genetics 0 works
- 9 Cancer survivorship and care Oncology 0 works
- 10 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has GEICAM – Spanish Breast Cancer Group's research output changed?
Output in 2018–2022 was 88% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Alcobendas
- Acciona (Spain)
- BP (Spain)
- Red Electrica de Espana (Spain)
- Fon (Spain)
- Solintel (Spain)
- Venter Pharma (Spain)
- Farmalder (Spain)
- Laboratorio Central de Sanitas
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.